US 12,698,335 B2Granted

Anti-BST2 antibodies targeting BST2 long isoform

AssigneeBoard of Regents, The University of Texas System

InventorsLaura Del Carmen Bover, Felipe Amaya-Manzanares, Long Vien, Ahmed Muhsin, Janis D Johnson, Julio Pollarolo, Zhuang Wu

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

Embodiments of the disclosure include methods and compositions directed to targeting of cells that express the long form of Bone marrow stromal cell antigen 2 (BST2) protein, including cancer cells that express the long isoform of BST2. In particular embodiments, monoclonal antibodies or functionally active fragments thereof are utilized to target cells that express the long isoform of BST2. The monoclonal antibodies or functionally active fragments thereof may be utilized by themselves or as part of other entities, such as cells or engineered antigen receptors. The disclosure includes methods of treatment, prevention, and/or diagnosis using the encompassed antibodies or functional fragments thereof.

Claims11

Dependent claims

An antibody or an antigen-binding portion thereof comprising:

(a) three heavy chain CDRs (CDR-H) and three light chain CDRs (CDR-L), wherein:
CDR-H1 comprises the amino acid sequence as set forth in SEQ ID NO:
8 (GFNIKDYY), CDR-H2 comprises the amino acid sequence as set forth in SEQ ID NO:
10 (IDPENGDT), CDR-H3 comprises the amino acid sequence as set forth in SEQ ID NO:
12 (KRGD), CDR-L1 comprises the amino acid sequence as set forth in SEQ ID NO:
17 (QSIVHSNGNTY), CDR-L2 comprises the amino acid sequence of KVS, and CDR-L3 comprises the amino acid sequence as set forth in SEQ ID NO:
20 (FQGSHAPFT);
and wherein said antibody or antigen-binding portion thereof binds to BST2;
(b) three heavy chain CDRs (CDR-H) and three light chain CDRs (CDR-L), wherein:
CDR-H1 comprises the amino acid sequence as set forth in SEQ ID NO:
38 (GYTFTEDT), CDR-H2 comprises the amino acid sequence as set forth in SEQ ID NO:
40 (INPNKGGT), CDR-H3 comprises the amino acid sequence as set forth in SEQ ID NO:
42 (ATLVDY), CDR-L1 comprises the amino acid sequence as set forth in SEQ ID NO:
30 (QNVGTN), CDR-L2 comprises the amino acid sequence of SAS, and CDR-L3 comprises the amino acid sequence as set forth in SEQ ID NO:
33 (QQYNSYPLT);
or
(c) three heavy chain CDRs (CDR-H) and three light chain CDRs (CDR-L), wherein:
CDR-H1 comprises the amino acid sequence as set forth in SEQ ID NO:
55 (GFSLSTSGVG), CDR-H2 comprises the amino acid sequence as set forth in SEQ ID NO:
57 (IWWDDDE), CDR-H3 comprises the amino acid sequence as set forth in SEQ ID NO:
59 (ARRYYGDAMDY), CDR-L1 comprises the amino acid sequence as set forth in SEQ ID NO:
47 (QSLVHSNGHTY), CDR-L2 comprises the amino acid sequence of KVS, and CDR-L3 comprises the amino acid sequence as set forth in SEQ ID NO:
50 (SQSTHVPYT).

20 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/002,014Filed 17 Jun 2021 · us provisional application
Priority: 19 Jun 2020
Published: US 2023/0235074 A127 Jul 2023
Granted: 4 Aug 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification29 codes

A61P 35/00
Antineoplastic agents
C07K 16/2896
Against receptors, cell surface antigens or cell surface determinants: against molecules with a "CD"-designation, not provided for elsewhere
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]

Family

Application63/041,421Us provisional application · filed 19 Jun 2020
Application63/041,450Us provisional application · filed 19 Jun 2020
Application63/152,811Us provisional application · filed 23 Feb 2021
US 2023/0235074 A1Pre-grant publication · published 27 Jul 2023
US 12,698,335 B2This patent

From the US filing history. Foreign family members aren’t listed.